Biovie Inc.

BIVI

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001580149


None

No letter

4 of 14 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $14.3M
Warnings	short runway, thin data not computable: dilution, degenerate inputs, distress, fortress balance sheet
Inputs computable	4 of 14
Graded from	filings received through Aug 13, 2026 92 days before the rescan; latest periodic filing 10-Q received Nov 6, 2026
Last close	$1.19 2026-11-12; market equity $0; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Aug 13, 2026

or "our") is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative of NeurMedix, Inc. ("NeurMedix") a privately held clinical-stage pharmaceutical company and a related party in June 2021. The acquired assets included NE3107 ("bezisterim"). Bezisterim, the approved generic name for NE3107 is an investigational, novel, orally administered small molecule that is thought to inhibit inflammation-driven insulin resistance and major pathological inflammatory cascades with a novel mechanism of action.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 25.7						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing					
Accruals ratio	(17.0%)	(6.6%)	25.7	800	2026-06-30
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 72.0					
Twelve-month failure probability	not computable	0.08%			
firm-wide XBRL shares cannot be assigned to one ticker class					
Altman Z double-prime	(89.06)	(0.35)	93.7	744	2026-06-30
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
interest expense must exceed $100,000					
Current ratio	3.59x	2.95x	50.2	826	2026-06-30
Growth and financing, sleeve percentile 89.8					
Revenue growth, three-year compound	not computable	10.1%			
four annual observations are required; found 0					
Free cash flow growth, three-year compound	not computable	11.0%			
four consecutive annual FCF observations are required; found 0					
Reinvestment rate	not computable	37.1%			
one or more required annual facts are missing					
Asset growth, three years	(26.0%)	2.2%	89.8	694	2026-06-30
Net share issuance, one year	not computable	2.5%			
firm-wide XBRL shares cannot be assigned to one ticker class					

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 4.9 months
Thin data	4 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-12 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(13.1%)	(1.9%)	41
Distance from 52-week high	(47.8%)	(30.8%)	32
EBIT to enterprise value	not computable	(1.9%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	not computable	0.28	
Sales to price	not computable	0.29	
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	(0.31)	(0.19)	41

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2026-06-30	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$7.7M
Operating cash flow, four quarters	-$18.9M
Months of runway	4.9
Days since last periodic filing	7 (10-Q received Nov 6, 2026)
Median daily dollar volume, 63 sessions	$379,566

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$22.1M	2026-06-30	2026-08-13	10-K	26-000332
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$19.0M	2026-06-30	2026-08-13	10-K	26-000332
3	assets	us-gaap:Assets	$14.3M	2026-06-30	2026-08-13	10-K	26-000332
4	assets	us-gaap:Assets	$21.6M	2025-06-30	2026-08-13	10-K	26-000332
5	current assets	us-gaap:AssetsCurrent	$13.6M	2026-06-30	2026-08-13	10-K	26-000332
6	current liabilities	us-gaap:LiabilitiesCurrent	$3.8M	2026-06-30	2026-08-13	10-K	26-000332
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$374.3M	2026-06-30	2026-08-13	10-K	26-000332
8	operating income	us-gaap:OperatingIncomeLoss	-$22.7M	2026-06-30	2026-08-13	10-K	26-000332
9	book equity	us-gaap:StockholdersEquity	$10.3M	2026-06-30	2026-08-13	10-K	26-000332
10	liabilities	us-gaap:Liabilities	$4.0M	2026-06-30	2026-08-13	10-K	26-000332
11	interest expense	us-gaap:InterestExpense	$17,901	2026-06-30	2026-08-13	10-K	26-000332
12	assets	us-gaap:Assets	$25.2M	2024-06-30	2025-08-15	10-K	25-000268
13	assets	us-gaap:Assets	$35.1M	2023-06-30	2024-09-30	10-K	24-000324

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.